18 CAMPUS BLVD., NEWTOWN SQUARE, PA
Reports Third Quarter 2025 Financial Results
Arrivent Unveils Firmonertinib Study Results for EGFR Mutant Lung Cancer at 2025 Lung Cancer Conference
Reports Second Quarter 2025 Financial Results
Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Arrivent Reports Positive Firmonertinib Study Results for EGFR Mutant Lung Cancer
Shareholder votes
Reports First Quarter 2025 Financial Results
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Certificate
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership